ArticleBiochemical genetics2026
TMEM44 as a Novel Prognostic Marker for Hepatocellular Carcinoma is Associated with Tumor Invasion, Migration, and Apoptosis.
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The transmembrane protein (TMEM) family represents a class of integral membrane proteins that traverse the lipid bilayer and play pivotal roles in diverse cellular processes. Functioning as molecular channels or regulators, TMEM proteins mediate selective transmembrane transport and have been implicated in the pathogenesis and progression of multiple malignancies. However, the biological significance of TMEM44 in hepatocellular carcinoma (HCC) remains largely unexplored. Through integrated bioinformatics analysis of clinical datasets, we identified significant upregulation of TMEM44 in HCC tissues, which correlated with adverse prognostic indicators. This overexpression was further validated at both protein and transcriptional levels via Western blotting and quantitative reverse transcription PCR (RT-qPCR) in HCC-derived cell lines and patient specimens. Functional characterization employing loss-of-function approaches in HCCLM3 and Huh-7 cell models demonstrated that TMEM44 silencing markedly attenuated malignant phenotypes: Transwell migration assays and wound healing analysis revealed impaired cellular motility, while 5-ethynyl-2'-deoxyuridine (EdU) incorporation assays showed suppressed proliferation. Furthermore, flow cytometric analysis indicated induced cell cycle arrest at the G0/G1 phase and enhanced apoptotic susceptibility upon TMEM44 knockdown. Collectively, our results identify TMEM44 as a critical oncogenic regulator in HCC, underscoring its dual potential as a prognostic biomarker and a therapeutic target for precision oncology.
Indexed as
Identifiers
40540157What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.